Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Terns Pharmaceuticals  (Stock symbol: TERN )

1065 East Hillsdale, Suite 100
Foster City, CA 94404
USA
(650) 525-5535
Website Company Summary Management Team
Management

CEO: Senthil Sundaram (7/31/2020) ; Weidong Zhong (4/30/2017)
President/COO/Operations: Diana Chung (11/30/2020) ; Bryan Yoon (11/30/2020) ; Erin Quirk (1/31/2019)
General Management: Martijn Fenaux (4/30/2017) ; Matt Duan (2018)
Finance: Mark Vignola (8/17/2020)
Board

Outside board: (May no longer be on the board) Carl L. Gordon (OrbiMed) Yi Shi (Lilly Asia Ventures Managing Partner) David Liu (Vivo Capital Principal) Elise Wang (Deerfield Partner)
Former outside board: Stella Shi (Lilly Asia Ventures Principal)
Company

Business description: Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.
Capital

Rounds: 3
Recent Fundings: Jan 2021   Oct 2018
Capital raised: 197.0M
Last Round: 87.0M
Ownership: Public   Ipo Filing
Stock Symbol: TERN
VCs include: Vivo Capital OrbiMed ;  Eli Lilly and Company ;  Decheng Capital ;  Deerfield Management Company ;  Lilly Asian Ventures ;  Samsara Capital ;  Suvretta Capital Management

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2021
Sector: Biotech
Year Founded: 2016
Headcount: 26-50 as of Jan 2021
Rounds: 3
Recent Fundings: Jan 2021   Oct 2018
Capital Raised: 197.0M
Last Round: 87.0M
Ownership: Public   Ipo Filing
Stock Symbol: TERN